Related Experiment Video
Updated: May 22, 2026
09:33
An Acute Retinal Model for Evaluating Blood Retinal Barrier Breach and Potential Drugs for Treatment
Published on: September 13, 2016
Vigabatrin-associated retinal damage: potential biochemical mechanisms.
Acta Neurologica Scandinavica
|May 29, 2012
Summary
Vigabatrin (VGB) treats seizures but can cause vision loss. Research suggests GABA excitotoxicity and taurine deficiency may underlie VGB
Area of Science:
- Neuroscience
- Ophthalmology
- Pharmacology
Background:
- Vigabatrin (VGB) is an effective anti-seizure medication.
- VGB use is limited by risks of retinopathy and visual field defects.
- Understanding VGB's cellular toxicity mechanisms is crucial.
Purpose of the Study:
- To review and analyze literature on VGB-mediated cellular toxicity.
- To explore potential pathophysiologic mechanisms of VGB's ocular side effects.
Main Methods:
- Literature review of existing studies on Vigabatrin.
- Analysis of animal data regarding GABA and taurine.
- Examination of cellular toxicity pathways.
Main Results:
- Animal data indicate gamma-aminobutyric acid (GABA) may mediate neural excitotoxicity.
- Taurine, concentrated in retinal cells, might be involved in VGB-induced retinal degeneration.
- Potential phototoxicity is also considered.
Conclusions:
- VGB-induced retinopathy may involve GABAergic excitotoxicity.
- Taurine deficiency could play a role in VGB's ocular toxicity.
- Further research is needed to elucidate these mechanisms.
Related Concept Videos
01:27Diabetic Retinopathy
DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...